share_log
Hi,
moomoo ID:0
Log Out
English
Back
  • English
  • 中文繁体
  • 中文简体

Sector Update: Health Care Stocks Retreating on Thursday

MT Newswires ·  09/30 01:54

01:53 PM EDT, 09/29/2022 (MT Newswires) -- Health care stocks were mostly lower this afternoon, with the NYSE Health Care Index sinking 0.8% and the SPDR Health Care Select Sector ETF (XLV) down 0.9%.

The Nasdaq Biotechnology index also was sinking 1.9%.

In company news, Editas Medicine (EDIT) slid 8.8% after BofA Securities began coverage of the genome editing company with a neutral stock rating.

MorphoSys (MOR) has turned narrowly lower, giving back an early 2.4% gain, after late Wednesday announcing new data showing that a combination of its Monjuvi drug candidate and lenalidomide chemotherapy followed by Monjuvi alone provided long-term efficacy in patients with relapsed or refractory diffuse large B-cell lymphoma.

Windtree Therapeutics (WINT) gained almost 4% after late Wednesday saying its istaroxime drug candidate met its primary endpoint of significantly improving systolic blood pressure in patients experiencing cardiogenic shock due to heart failure compared with patients in the control group of the phase 2 study. The improved blood pressure persisted over 24 hours, the company said, adding that istaroxime also produced a substantial increase in the amount of blood pumped by the heart without increasing heart rate.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.